Abstract

War and the ensuing health system breakdowns in the Islamic State (IS)–occupied Syria and Iraq significantly increase the risk of a new wave of infectious disease epidemics in the Middle East and North Africa (MENA). Proactive engagement to enable health system capacity and resilience—including expanding immunization programs and building biotechnology capacity for vaccines that specifically target diseases in the region—would help minimize the impact if and when outbreaks occur. A program of vaccine science diplomacy with selected countries in the MENA region could help to avert an international public health crisis possibly similar in scope and magnitude to the 2014 Ebola virus outbreak in West Africa. The 2014 Ebola outbreak emphasized strong links between the forces of poverty, depletions in public health and environmental degradations as a result of long-standing conflicts in West Africa, and the emergence of a catastrophic neglected tropical disease (NTD). A stark reality is that such links between poverty, war, and NTDs are not new, but have been reoccurring for decades [1]. For example, beginning in the 1970s and lasting throughout much of the 20th century, hundreds of thousands of people may have perished from African sleeping sickness—human African trypanosomiasis, a parasitic infection transmitted by tsetse flies—in Angola, Democratic Republic of Congo, and Sudan because of civil wars in those countries and the inability to mount effective public health control measures [2]. Kala-azar—visceral leishmaniasis, another parasitic infection but transmitted by sandflies—killed an estimated 100,000 people in conflict-ridden southern Sudan between 1986 and 1995 [3]. Because journalists had limited access to these war-torn areas, both epidemics went mostly unrecorded and unacknowledged. The latest example is the collapsed health systems of post-conflict Liberia and Sierra Leone that were unable to cope with an Ebola epidemic that infected more than 20,000 people and caused approximately 10,000 deaths by the early part of 2015.

Highlights

  • War and the ensuing health system breakdowns in the Islamic State (IS)–occupied Syria and Iraq significantly increase the risk of a new wave of infectious disease epidemics in the Middle East and North Africa (MENA)

  • While pockets of science and technology have advanced in the MENA region, overall vaccine biotechnology has lagged

  • In terms of manufacturers that produce vaccines accessible for developing countries and belong to the Developing Country Vaccine Manufacturers Network (DCVMN), only four come from the MENA region—one each in Saudi Arabia (AraBio) and Egypt (Vacsera), and two in Iran (Institut Pasteur and Razi Vaccine and Serum Research Institute) [23,24,25], and none produces vaccines that are pre-qualified by the World Health Organization (WHO) for export [32]

Read more

Summary

OPEN ACCESS

Citation: Hotez PJ (2015) Vaccine Science Diplomacy: Expanding Capacity to Prevent Emerging and Neglected Tropical Diseases Arising from Islamic State (IS)–Held Territories. PLoS Negl Trop Dis 9(9): e0003852. doi:10.1371/journal.pntd.0003852 Funding: The author received no specific funding for this work. Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: I am the principal investigator on vaccines in clinical trials against hookworm and schistosomiasis and principal investigator on several other vaccines in development against NTDs. The views presented herein are those of the author and not necessarily those of the US Department of State or the US Government.

Introduction
Neglected Diseases and Emerging Infections in the MENA
Visceral leishmaniasis MERS Leprosy Trachoma
New Vaccines for the MENA
Morocco and Tunisia
Saudi Arabia
Next Steps and Concluding Remarks
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call